MedTrace Logo

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

NCT00323583 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2007-05-08

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, oxaliplatin, leucovorin and 5-fluoruracil, work in different ways separately and in combination to stop tumor cells from dividing so they stop growing or die. The use of metronomic dosing of chemotherapy minimizes side effects and increases efficacy by anti-angiogenic effects. The pilot study demonstrated promising responses in all patients. It is not yet known how effective this drug and dosing combination is in treating advanced pancreatic cancer.

PURPOSE: This non-randomized phase II trial is studying giving weekly doses of paclitaxel, oxaliplatin, leucovorin and 5-fluorouracil together as second or third-line therapy in treating patient with locally advanced unresectable or metastatic adenocarcinoma of the pancreas following demonstrated progression after first-line gemcitabine.

Conditions

  • Adenocarincoma of Pancreas
  • Stage III Pancreatic Cancer
  • Stage IVA Pancreatic Cancer
  • Stage IVB Pancreatic Cancer

Interventions

DRUG

paclitaxel

DRUG

oxaliplatin

DRUG

leucovorin

DRUG

5-fluorouracil

DRUG

glutathione

DRUG

calcium and magnesium

PROCEDURE

Chemotherapy

PROCEDURE

Chemoprotection

PROCEDURE

Complementary and alternative therapy

Sponsors & Collaborators

  • Seattle Cancer Treatment and Wellness Center

    lead OTHER

Principal Investigators

  • Ben Chue, MD · Seattle Cancer Treatment and Wellness Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00323583 on ClinicalTrials.gov